The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Pfizer said today it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Professor Nicholas Turner, from the Institute of Cancer Research, tells Sky News that capivasertib is a "great success story ...